Lauren Shea1, Neha Mehta-Shah2. 1. Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid, Box 8056, St. Louis, MO, 63110, USA. 2. Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid, Box 8056, St. Louis, MO, 63110, USA. mehta-n@wustl.edu.
Abstract
PURPOSE OF REVIEW: The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation. RECENT FINDINGS: Monotherapy with BV has proven to be effective and well tolerated in patients with relapsed/refractory (R/R) CD30-positive CTCL. BV has shown significant activity in R/R PTCL as well, with particularly durable responses in patients with anaplastic large cell lymphoma (ALCL). In a landmark phase III study (ECHELON-2), BV + CHP demonstrated superior progression-free and overall survival relative to CHOP as frontline therapy for patients with CD30-expressing PTCL, representing the first randomized trial demonstrating an overall survival benefit in PTCL. Though BV is overall well tolerated, peripheral neuropathy remains a clinically significant adverse effect. BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings. Key ongoing areas of investigation include optimization of CD30 expression as a predictive biomarker as well as the role of BV in consolidation therapy.
PURPOSE OF REVIEW: The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation. RECENT FINDINGS: Monotherapy with BV has proven to be effective and well tolerated in patients with relapsed/refractory (R/R) CD30-positive CTCL. BV has shown significant activity in R/R PTCL as well, with particularly durable responses in patients with anaplastic large cell lymphoma (ALCL). In a landmark phase III study (ECHELON-2), BV + CHP demonstrated superior progression-free and overall survival relative to CHOP as frontline therapy for patients with CD30-expressing PTCL, representing the first randomized trial demonstrating an overall survival benefit in PTCL. Though BV is overall well tolerated, peripheral neuropathy remains a clinically significant adverse effect. BV is a major therapeutic advance in the treatment of patients with R/R CTCL and of those with PTCL in both the R/R and frontline settings. Key ongoing areas of investigation include optimization of CD30 expression as a predictive biomarker as well as the role of BV in consolidation therapy.
Entities:
Keywords:
Brentuximab vedotin; Cutaneous T cell lymphoma; Peripheral T cell lymphoma
Authors: Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz Journal: J Clin Oncol Date: 2011-01-18 Impact factor: 44.544
Authors: J S Abramson; T Feldman; A R Kroll-Desrosiers; L S Muffly; E Winer; C R Flowers; F Lansigan; C Nabhan; L J Nastoupil; R Nath; A Goy; J J Castillo; D Jagadeesh; B Woda; S T Rosen; S M Smith; A M Evens Journal: Ann Oncol Date: 2014-09-05 Impact factor: 32.976
Authors: Ezogelin Oflazoglu; Kim M Kissler; Eric L Sievers; Iqbal S Grewal; Hans-Peter Gerber Journal: Br J Haematol Date: 2008-05-08 Impact factor: 6.998
Authors: Alejandro A Gru; Govind Bhagat; Antonio Subtil; Shyam S Raghavan; Melissa Pulitzer; Catherine Chung; Martin Sangueza; Jose A Plaza Journal: Am J Surg Pathol Date: 2021-06-01 Impact factor: 6.298
Authors: Jana Mihályová; Katarína Hradská; Tomáš Jelínek; Benjamin Motais; Piotr Celichowski; Roman Hájek Journal: Int J Mol Sci Date: 2021-10-25 Impact factor: 5.923